Skip to main content
SpringerLink
Log in

Haptoglobin-related protein as a serum marker in malignant lymphoma

  • Article
  • Published:
Pathology & Oncology Research

Abstract

A novel serum 21 kDa haptoglobin-related protein (Hpr) was investigated in patients with malignant lymphoma, to evaluate its correlation with clinical and histologic features at presentation and its possible role as a tumor marker for patient outcome. One hundred fifty eight serum samples were taken from 88 patients with non-Hodgkin’s lymphoma (n=58) and Hodgkin’s disease (n=30) at presentation and in the course of follow-up. Sera from 61 healthy volunteers served as normal controls. Serum Hpr levels in the lymphoma patients (median 430xl03 u/ml, range 0-4000xl03) were significantly higher than in the control group (median 68xl03 u/ml, range 0-180xl03) (p=0.0001). Higher median Hpr values were detected in patients with advanced disease (p=0.013), “B” symptoms (p=0.029) and in males (p=0.053). There was also a significant correlation between Hpr and erythrocyte sedimentation rate (p=0.028). Serial determinations showed a significant decrease of the initial Hpr values obtained after treatment in 41 patients, 38 of whom achieved complete remission. In the follow-up period additional Hpr measurements were taken from 17 patients. Three of them eventually relapsed, and showed increased Hpr levels at the time of relapse. Hpr levels remained low in 11 of 14 patients who maintained complete remission, and increased in three. In conclusion, serum Hpr is a new serum tumor marker of potential use in the clinical setting of lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Child JA, Spati B, lllingworth S, et al: Serum beta 2 microglobulin and c-reactive protein in the monitoring of lymphoma. Cancer 45:318–326, 1980.

    Article  PubMed  CAS  Google Scholar 

  2. Swan F, Velasquez WS, Tucker S, et al: A new serologic staging system for large-cell lymphomas based on initial 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518–1527, 1989.

    PubMed  Google Scholar 

  3. Blay JY, Farcet JP, Lavaud A, et al: Serum concentrations cytokines in patients with Hodgkins disease. Eur J Cancer 30A:321–324, 1994.

    Article  PubMed  CAS  Google Scholar 

  4. Shalitin C, Epelbaum R, Moskovitz B, et al: Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients. Cancer Detection and Prevention 18: 357–365, 1994.

    PubMed  CAS  Google Scholar 

  5. Shalitin C, Valensi C, Admon A, et al: Elavated levels of haptoglo-bin-related protein in sera of cancer patients. J Tumor Marker Oncol 13:15–25, 1998.

    Google Scholar 

  6. Tabak S, Lev A, Valansi C, et al: Transcriptionally active haptoglo-bin-related (Hpr) gene in hepatoma G2 and leukemia molt-4 cells. DNA and Cell Biology 15:1001–1007, 1996.

    Article  PubMed  CAS  Google Scholar 

  7. Maeda N: Nucleotide sequence of the haptoglobin and haptoglobin-related gene pair. J Biol Chem 260:6698–6709, 1985.

    PubMed  CAS  Google Scholar 

  8. Oliviero S, Morrone G, Cortese R: The human haptoglobin gene: transcribtional regulation during development and acute phase induction. EMBO J 6: 1905–1912, 1987.

    PubMed  CAS  Google Scholar 

  9. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkins disease staging classification. Cancer Res 31:1860–1861, 1971.

    PubMed  CAS  Google Scholar 

  10. Rosenberg SA, Berard CW, Brown BW, et al: National cancer institute sponsored study of classifications of non-Hodgkins lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 49:2112–2135, 1982.

    Article  Google Scholar 

  11. Shalitin C, Epelbaum R, Moskovitz B, et al: Enzyme-linked immunosorbent assay for the detection of a novel 21 kDa protein associated with the clinical course of patients with urogenital tumors. Int J Oncol 1:107–112, 1992.

    CAS  Google Scholar 

  12. Knee TS, Osband MS, Carpinito G A, et al: Acute phase reactants and suppressive E-receptor factor in various groups of patients receiving autolymphocyte therapy. Cancer Detection and Prevention 15: 189–197, 1991.

    PubMed  CAS  Google Scholar 

  13. Ljungberg B, Grankvist K, Rasmuson T: Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 76:1435–1539, 1995.

    Article  PubMed  CAS  Google Scholar 

  14. Buccheri G, Ferrigno D: Prognostic significance of the serum protein content in lung cancer. Eur Respir J 7 (Suppl 18): 389s, 1994.

    Google Scholar 

  15. Hannisdal E, Tveit KM, Theodorsen L, et al: Host markers and prognosis in current rectal carcinoma treated with radiotherapy. Acta Oncol 33:415–421, 1994.

    Article  PubMed  CAS  Google Scholar 

  16. Onizuka K, Migita S, Yamada H, et al: Studies on serum protein fractions of patients with uterine cervical cancer undergoing radiotherapy: relationship between changes in serum protein fractions and prognosis. Nippon Igaku Hoshasen Gakkai Zasshi 54:1007–1017, 1994.

    PubMed  CAS  Google Scholar 

  17. Shah I, Lewkow LM, Khilanani U: Correlation of hypercupremia with other acute phase reactant in malignant lymphoma. Cancer 51:851–854, 1983.

    Article  PubMed  CAS  Google Scholar 

  18. Hagberg H, Glimelius B, Gronowitz S, et al: Biochemical markers in non-Hodgkins lymphoma stages III-IV and prognosis: A multi-variate analysis. Scan J Haematol 33:59–67, 1984.

    CAS  Google Scholar 

  19. Martinsson U, Glimelius B, Hagberg H, et al: Primarily asymptomatic low-grade non-Hodgkin lymphoma: prediction of symptom-free survival and total survival. Eur J Haematol 43:332–338, 1989.

    Article  PubMed  CAS  Google Scholar 

  20. Desai SS, Ishwad CS, Balakrishnan V, et al: Serum haptoglobin level in patients with malignant lymphoma and its clinical significance. Indian J Cancer 27:46–54, 1990.

    PubMed  CAS  Google Scholar 

  21. Oh SK, Very DL, Walker J, et al: An analogy between a potent I immunosuppressant in cancer and fetal haptoglobin. Cancer Res 47:5120–5128, 1987.

    PubMed  CAS  Google Scholar 

  22. Kuhajda FP, Piantadosi S, Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636–641, 1989.

    PubMed  CAS  Google Scholar 

  23. Kuhajda FP, Katuprutuwa AI, Pasternack GR: Expression of haptoglobin-related protein and its potential role as tumor antigen. Proc Natl Acad Sci USA 86: 1188–1192, 1989.

    Article  PubMed  CAS  Google Scholar 

  24. Shurbaji MS, Kuhajda FP, Pasternack GR, et al: Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. Am J Clin Pathology 97:686–691, 1992.

    CAS  Google Scholar 

  25. Kuhajda FP, Jenner K, Wood FD, et al: Fatty acid synthesis: A potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379–6383, 1994.

    Article  PubMed  CAS  Google Scholar 

  26. Grunder-Culemann E, Bokemeyer C, Neubauer V, et al: Analysis of a non-ras 21 kDa protein in patients with metastatic testicular germ-cell tumors. J Cancer Res Clin Oncol 119:685–688, 1993.

    Article  Google Scholar 

  27. Shalitin C, EpelbaumR, Valansi C, et al: Detection of a 21 kDa protein in sera of patients with urogenital tumors. Cancer J 74–78, 1990.

  28. Shalitin C, Epelbaum R, Valansi C, et al: A novel 21 kDa protein as a serum marker for benign and malignant urogenital tumors: preliminary communication. Int J Cancer 49:861–866, 1991.

    Article  PubMed  CAS  Google Scholar 

  29. Shalitin C, Moskovitz B, Livne PM, et al: Serial levels of p21 before and after surgery in patients with renal cell carcinoma, in Guiliani L, Puppo P, eds. Urology 1992. Monduzi Editore, Bologna, Italy, 325–329, 1992.

    Google Scholar 

  30. Shalitin C, Valanci C, Lev A, et al: Cell-cycle inhibition in human BE-13 T-cell leukemia cells by haptoglobin-related (HPR) anti-sense cDNA. Anticancer Res 18:1745–1750, 1998.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Rambam Medical Center, 31096, Haifa, Israel

    Ron Epelbaum, Ruth Segal, Michelle Leviov, Menahem Ben-Shahar & Nissim Haim

  2. Department of Biology, Technion-Israel Intitute of Technology, Israel

    Channa Shalitin & Clari Valansi

  3. Department of Statistics, University of Haifa, Haifa, Israel

    Ida Arselan & David Faraggi

Authors
  1. Ron Epelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Channa Shalitin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruth Segal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Clari Valansi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ida Arselan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Faraggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michelle Leviov
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Menahem Ben-Shahar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nissim Haim
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work is dedicated to the memory of Dr. Arie H. Bartal, a dedicated oncologist and friend. This work was supported by Chemotech Thechnologies Ltd., by grant no. 3676 from the Chief Scientist’s Office of the Ministry of Health, Israel, and by the Fund for Promotion of Research in the Technion.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Epelbaum, R., Shalitin, C., Segal, R. et al. Haptoglobin-related protein as a serum marker in malignant lymphoma. Pathol. Oncol. Res. 4, 271–276 (1998). https://doi.org/10.1007/BF02905217

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02905217

Key words

Search

Navigation